Overview

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Status:
Terminated
Trial end date:
2021-06-28
Target enrollment:
Participant gender:
Summary
Prospective national multicenter randomized open label phase IIb RUXBETA trial.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
French Innovative Leukemia Organisation
Collaborator:
Novartis Pharmaceuticals
Treatments:
Anagrelide
Hydroxyurea